New
chapters.

Released Q2 2026 financial results.

Q2 revenue was $10.7 million, up 9%, and ARR was $42.3 million, up 11%. Management raised adjusted EBITDA guidance and expects an annualized adjusted EBITDA run rate above $15 million exiting 2026.

Annual meeting: directors elected and auditor proposal voted on.

Named Matthew Domeyer CFO effective July 20, completing the finance succession after Kelly Georgevich became CEO.

Furnished an updated investor presentation.

Formalized Nancy Curtin's interim-CEO employment contract and amended President/COO Kevin Moran's agreement; Moran's salary rose to $600,000 with a $1.6 million 2026 target bonus.

CFO Michael Harrington retired; Patrick Keenan appointed CFO effective July 1. The interim CEO appointment sits within a broader leadership transition.

Extended the Fremont facility lease through June 2034, with two further five-year extension options.

Released Q2 2026 business and financial results.

Q2 revenue rose 126% to $34 million, with a 27% gross margin and $5.1 million net loss. Raised 2026 revenue guidance to at least $140 million and adjusted EBITDA to at least $4 million.

Annual meeting elected directors, including Tom Stepien, and ratified the auditor.

Released Q2 2026 financial results.

Q2 revenue rose 19% to $8.4 million; first-half operating cash flow was $4.4 million. These operating results should be assessed alongside the lender restrictions described below.

Fifth Third agreed to conditional forbearance through June 30, 2027, required a sale of all or part of the assets and blocked new revolver advances. The executive chairman’s entity supplied a $2 million secured subordinated loan at 10% capitalized interest plus warrants for 220,000 shares at $1.45. This is a lender-driven sale process.

CFO Raymond Frech resigned; CAO Alexis Tirrito (Wallace) became interim CFO. Combined with an interim CEO and lender forbearance, this is a restructuring situation.

Released Q2 2026 results and supplemental investor presentation.

Q2 net investment income was $0.28/share and NAV was $10.94/share versus $11.02 in the prior quarter; the quarterly dividend was $0.26/share.

Replaced the Sierra credit-support agreement: adviser agreed to pay approximately $67.0 million on termination of the old agreement; new protection covers approximately $11.0 million of remaining investments, with settlement mechanics extending to 2032.

Released Q1 results, furnished an investor presentation and reported director-election results.

Released Q2 2026 financial results.

Q2 revenue declined 9.5% to $44.2 million; adjusted EBITDA was $5.6 million and net loss was $7.4 million. A voluntary recall weighed on revenue and gross margin.

Amendment established interim CEO Peterson's $658,800 base salary, 72.5% incentive opportunity and option grant covering 0.56% of outstanding shares, with an additional equivalent grant if made permanent CEO.

Christensen resigned effective June 8; Peterson became interim CEO of BioTE Medical and Marc Beer became executive chairman. Christensen remained a director.

Released results for the quarter ended July 31, 2026.

Fiscal Q1 2027 revenue rose 53% to $30.781 million, operating income rose 59% to $7.424 million and net income rose 43% to $5.265 million. The release contains conflicting headline EPS figures, so this summary uses the income-statement dollar amounts.

Renewed Kansas sports-wagering management for three years from September 2027 and announced a ten-year extension of the DraftKings agreement, subject to continuing state authority.

Set Sefchick's CFO pay and interim-CEO compensation, including an additional $10,000 monthly while interim and a $25,000 bonus contingent on successfully onboarding a new CEO. This supports an ongoing permanent search.

Added Matthew McBrady, GoPuff parent GoBrands' CFO, to the board.

Furnished an updated investor presentation.

Rose Lopez Keravuori replaced Emily Rooney on the board; updated risk-committee arrangements and annual-meeting nomination deadlines.

Released Q2 2026 results.

Q2 total revenue was $63.3 million, up 5%, including $57.4 million product revenue, up 10%. Full-year product revenue guidance was $229–231 million and INTERCEPT Fibrinogen Complex revenue guidance was $23–25 million.

Formalized former CEO Greenman’s move to executive chairman effective July 1.

Refinanced term-loan and revolving credit agreements with MidCap; the new CEO inherits revised liquidity arrangements.

Corrected earnings-call/deck disclosure about the divested Regulatory and Medical Writing business: approximately $17 million of 2025 adjusted EBITDA includes unallocated overhead; excluding corporate expense retained by Certara, the figure is approximately $23 million.

Released Q2 2026 financial results.

Continuing-operations Q2 revenue was $93.3 million, up 1%: software grew 4% to $48.8 million while services declined 3% to $44.5 million. Adjusted EBITDA declined 3% to $26.2 million; announced an additional $50 million repurchase authorization.

President/Chief Commercial Officer Leif Pedersen departed that role effective August 1; advisory employment continues through year-end before a termination without cause.

Approved the OpGen-to-CapForce name change, associated ticker change and a one-million-share incentive plan; reported annual-meeting results.

Disclosed acquisition of the iCapX cap-table-management business from controlling shareholder AEI for approximately $12.28 million in stock. Related-party valuation and advisory-fee recognition deserve scrutiny.

Amended the AEI equity financing arrangement and disclosed President David Lazar's resignation effective January 8, 2026. Latest retrieved 8-K is February 27, so the filing stream is stale relative to the research date.

Released Q2 results and declared a $0.35 third-quarter dividend, payable October 16 to September 30 holders.

Q2 net investment income and adjusted net investment income were each $0.35/share. NAV fell 1.8% sequentially to $15.61/share.

Announced the Q2 earnings-call date.

Shareholders approved authority to issue common shares below NAV for the following 12 months, subject to board approval and stated limitations. Approval is financing flexibility, not evidence that shares have already been issued.

Confirmed a preliminary, non-binding possible cash offer for SThree; no firm offer or completed acquisition.

Amended the Lyneer/SPP settlement disclosure and Nasdaq minimum-bid-price deficiency; the amended notice gives a February 9, 2027 cure deadline.

Original settlement and listing-deficiency disclosure, subsequently amended August 19; do not treat the amendment as a separate transaction.

Formalized departing CFO Laurent Mercier’s transition to strategic CEO adviser after September 1; advisory arrangements run through June 2027.

Named Soraya Benchikh CFO effective September 1, succeeding Mercier.

Released June-quarter financial results and outlook.

Fiscal Q4 sales grew 1% as reported but declined 1% like-for-like. Fiscal 2026 operating cash flow was $538 million and free cash flow was $348 million.

TRA holders waived accelerated termination payments for change-of-control transactions with definitive merger agreements signed by December 31, 2026. Other tax-benefit payment rights remain; this is a limited waiver rather than forgiveness of every TRA obligation.

Received a non-binding Advent proposal to buy unaffiliated Class A shares and OpCo units for $1.02 cash each; special committee reviewing.

Named Clay Ritchey CEO effective September 8, with healthcare technology operating experience.

Released Q2 results and investor presentation.

Q2 revenue declined to $7.4 million from $8.0 million; ARR declined to $11.6 million from $15.9 million. Cash, cash equivalents and marketable securities totaled $8.8 million at June 30; Q2 free-cash-flow usage was $1.0 million.

Riley McCormack left the board; new CEO Paul Carreiro filled the vacancy.

Set Carreiro’s inducement equity terms and disclosed substantial doubt about going concern: $9.0 million of cash/marketable securities at May 31 was insufficient for 12 months of planned operations absent revenue growth, new capital or cost reductions.

Appointed Joshua Lev and Michael Fox co-CEOs/presidents; amended bylaws and reported annual-meeting votes. Both retain CFO/COO responsibilities respectively.

Released Q2 results and guidance covering 2026 and certain periods of 2027.

Q2 revenue grew 28% to $9.5 million, with a $3.1 million net loss. Management raised 2026 revenue growth guidance to over 30% and targeted positive adjusted EBITDA in Q3 2027.

Released Q1 results and full-year 2026 guidance.

Raj Talluri resigned; CFO Ryan Benton became interim CEO and T.J. Rodgers executive chairman. Q3 guidance was reaffirmed in the transition announcement.

Released Q2 2026 financial results.

Q2 revenue grew 21% to $9 million, with a 14.4% gross margin. Management expected final smartphone qualification testing during 2026; qualification and volume production remain distinct milestones.

Named Michael Vyvoda COO effective July 29. The subsequent CEO change follows an operations leadership change.

Released Q2 and first-half results.

Q2 revenue was $12.0 million versus $28.1 million a year earlier. Gross margin was 74.7%, but adjusted EBITDA was a $2.6 million loss; cash and investments totaled $98.1 million.

Added John Mitchell to the board.

Amendment established interim CEO Alex Buehler’s $645,000 salary and eligibility for a success bonus linked to the next permanent CEO starting.

Released Q2 2026 financial results.

First-half deliveries were 485,000 pounds at $70.10/lb, against a $75.54/lb weighted-average delivered cost, including purchased material. Extraction fell to 131,274 pounds from 317,613; unrestricted cash was $21.8 million. The reported $88.4 million total liquidity also includes securities and inventory, and is not equivalent to cash.

Finalized the separation agreement with former CEO Robert Willette; the April termination was treated as without cause.

Annual meeting approved all submitted matters, including election of new CEO Richard Little to the board.

Released Q2 results and supplemental presentation.

Q2 distributable earnings were $0.25/share versus a $0.20 dividend; fully converted GAAP book value increased $0.06 to $14.24/share. Repurchased $16.0 million of common shares; the average portfolio risk rating improved to 2.4 from 2.5.

Reported annual-meeting director, auditor and compensation votes.

Released Q1 results and supplemental presentation.

Released Q2 results, earnings presentation and financial supplement.

Q2 net income rose 61% year over year to $3.8 billion, substantially helped by a credit reserve release. Net revenues rose 1% to $6.0 billion; net worth reached $78 billion.

Launched a cash tender for selected STACR credit-risk-transfer notes; debt/liability management.

Released Q1 results, earnings presentation and financial supplement.

Released Q2 results alongside the quarterly report, earnings presentation and financial supplement.

Q2 net income was $4.0 billion versus $3.7 billion in Q1, and net worth was $116.5 billion. The release identifies Peter Akwaboah as acting CEO, confirming that he is serving in that role.

Released Q1 results with earnings presentation and financial supplement.

Launched cash tenders for selected Connecticut Avenue Securities credit-risk-transfer notes.

Received a new Nasdaq sub-$1 bid-price notice, with a February 17, 2027 cure deadline.

Regained periodic-reporting compliance after filing the previously late Q1 10-Q on July 16.

Regained bid-price compliance in early July; that improvement subsequently reversed, as the August notice shows.

Furnished its quarterly results release.

Q2 net investment income was $0.32/share and NAV was $7.95/share, up approximately 3% sequentially. The adviser waived $0.9 million of quarterly incentive fees; the board declared a $0.25/share Q3 distribution.

Called $6.5 million of 8.50% notes due 2029 for redemption at par plus accrued interest on August 19.

Extended the City National revolving facility to June 8, 2029, or March 31, 2029 if the 8.50% notes are not refinanced.

Promoted Greg Hanselman to COO effective August 20.

Released Q2 financial results.

Q2 revenue was $47 million and adjusted EBITDA was $11 million. Exiting the South Dakota ATJ-60 project and other non-core activities drove a $176 million noncash impairment and $177 million net loss. Raised full-year adjusted EBITDA expectations to more than $60 million.

Appointed Todd Werpy to the board, with the filing specifying an August 20 effective date.

Furnished an updated corporate presentation.

Furnished an earlier updated corporate presentation.

Released Q2 and first-half results. CEO appointment arose from the May Cullgen transaction, rather than these presentation updates.

Q2 revenue was $29.1 million; reaffirmed 2026 revenue guidance of $100.5–111.0 million. China’s regulator accepted the F351/hydronidone application for CHB-induced liver fibrosis in May; acceptance is a review milestone, not marketing approval.

Announced Simeon Kohl will replace Ben Albert on September 14. Albert himself became CEO February 12, so this is a second 2026 handoff.

Closed the $147 million VitalWare sale; used proceeds plus cash to repay approximately $159.95 million of loan principal, plus premium/interest/fees, and terminate the credit facility. Also released Q2 results and transaction pro formas.

Q2 revenue declined 13% to $70.487 million while adjusted EBITDA increased 6% to $9.919 million. The same filing contains the VitalWare disposal and debt repayment, making comparability and the remaining business important.

Reported annual-meeting votes.

Released Q2 results and earnings presentation.

Added Elena Poptodorova as an independent trustee and reported annual-meeting votes.

Furnished an investor presentation.

Authorized a $0.1356/share distribution to June 30 holders, expected to be paid in early July.

Authorized a $0.1356/share distribution to March 31 holders, expected to be paid in early April.

Bernard Michael succeeded retiring CEO Mark Zalatoris effective February 2.

Restructured the master lease covering 545 childcare centers into six site groups with expirations from 2029 through 2042. The cap on applicable periodic rent escalation increased from 10% to 12.5%, subject to the contractual index formula.

Released Q2 results for the quarter ended July 4.

Q2 revenue declined 0.4% to $697.5 million; early-childhood enrollment declined 4.0%, partly offset by tuition increases. Net loss was $8.8 million and adjusted EBITDA was $63.0 million.

Added David Barse as an independent director.

Amendment supplied acquired CCF/Aaron’s interim financials and combined pro forma financial statements.

Dismissed Grant Thornton as auditor; its prior audit reports included going-concern explanatory paragraphs. Engaged Elliott Davis, the existing auditor of acquired CCFI and Aaron’s; reported no accounting disagreements with Grant Thornton.

Extended the CCF subsidiary credit facility draw period by one month, from August 30 to September 30, 2026, before a potential 12-month amortization period.

Amended bylaws to clarify that director removal rests with a majority shareholder vote; filing says the board had not planned to remove a director.

Released Q2 results and a guidance update; the cover report contains a prior-year reference, so use the earnings exhibit for the actual outlook year.

Q2 revenue grew 18% to $12.0 million with 65.1% gross margin. The actual 2026 guidance was $47.5–48.5 million revenue and 62–64% gross margin. Withdrew the FreedomEDGE/Phesgo 510(k) submission and shifted development toward other oncology molecules; this changes the product catalyst.

Amended the Command Medical manufacturing/supply agreement, including duration, pricing, pass-through savings and second-site obligations.

Released Q2 results and a quarterly-dividend announcement.

Q2 revenue grew 13% to $558.1 million and net income was $15.2 million versus a $9.2 million loss a year earlier. Higher TiO2 volumes and lower production costs helped offset lower year-over-year selling prices.

Reported annual-meeting director elections and say-on-pay vote.

Furnished first-quarter financial results.

Formalized former CFO Taoufiq Boussaid’s advisory transition through year-end.

Drew another $400 million from the PIF-affiliate facility, bringing outstanding principal to $1.7 billion with roughly $800 million capacity remaining; also disclosed finance-leadership changes.

Registered resale of Ayar preferred/conversion shares and Uber-affiliate common shares. This is resale registration, not itself a new primary capital raise.

Released Q2 financial results.

Q2 revenue declined 5% to $22.8 million, including a 4% U.S. decline. Gross margin reached 78%; adjusted EBITDA loss improved 39%. International weakness included a lack of China sales while awaiting registration renewal.

Reported annual-meeting voting results.

Released Q1 financial results.

Released Q2 2026 financial results.

Q2 net income fell to $7.4 million from $11.1 million, largely reflecting lower equity-investment gains. Net interest income grew 7% to $57.2 million, originations grew 63% to $611.6 million and book value reached $17.62/share; repurchased $7.7 million of shares.

Accelerated vesting of 92,978 restricted shares for retiring Medallion Bank CEO Donald Poulton, preserved option expiration dates and approved eligibility for a discretionary annual bonus.

Annual meeting elected all three company nominees; shareholders rejected dissident BIMIZCI nominees, ratified the auditor and approved advisory executive compensation.

Received a Nasdaq minimum-bid-price deficiency and reshuffled directors/audit leadership, including Joe Conlon’s appointment.

Terminated CFO MeiLin Yu; successor not yet appointed in that filing.

Terminated the Tachyon 9 binding LOI without an early-termination penalty and announced a strategic AI-infrastructure initiative.

Added Nadav Kidron to the board. Disclosed that Infinite Epigenetics exclusivity expired July 15 and no definitive agreement had been reached as of August 18.

Released Q2 financial results.

Q2 revenue rose 12.1% to $29.0 million; adjusted EBITDA loss from continuing operations was $9.6 million. Cash, deposits, restricted deposits and marketable equity securities totaled $433.3 million. Announced a Markforged sale to Stratasys, expected to close in the second half, and completed AME/Fabrica disposals.

Murchinson settlement changed board control; David Stehlin departed and Moshe Rozenbaum became interim CEO. The filing expressly reports a change in control.

Promoted Gautam Ramdas to CEO and Brian Haglund to COO; former CEO Patrick Lynch became chairman.

Released fiscal Q3 results for the period ended May 31.

Fiscal Q3 revenue rose 12.6% to $24.216 million, but gross margin fell 477 basis points to 33.6%. Net loss was $263,000 versus $122,000 net income a year earlier: sales growth had not yet translated into earnings improvement.

Suspended the quarterly dividend to prioritize debt reduction.

Issued $35 million of subordinated notes due 2036 at an initial 7.50% fixed coupon, switching to floating after September 2031; proceeds for general corporate purposes.

Furnished the investor-call script, including forward earnings guidance.

Furnished Q2/first-half operating results and an investor presentation.

Q2 net income was $6.7 million versus $3.6 million a year earlier. Loans increased 11.6% sequentially to approximately $1.2 billion and deposits increased 11.1% to approximately $1.2 billion; diluted EPS reflects preferred-share conversion effects.

Annual meeting approved an additional 600,000 shares for the incentive plan and reported voting results.

Released Q2 results.

Q2 revenue grew 29.9% to $33.9 million; subscription revenue reached $3.2 million. Adjusted EBITDA was $2.9 million excluding the tariff-refund impact, versus $0.5 million a year earlier; including that impact it was $6.7 million.

Refinanced the existing ABL and WTI debt arrangements; an initial $17.063 million revolver draw partly repaid the old facilities.

Named Mark Van Oene CEO and announced an approximately 8% workforce reduction; targeted $30–40 million of annualized operating-expense reductions by end-2027 and roughly $2 million of restructuring charges. Also released Q2 results.

Q2 revenue was $39.0 million. Began the global SPRQ-Nx commercial rollout at a $345 list price per genome and commenced sequencing/sample delivery for Basecamp Research. These commercial milestones sit alongside the CEO change and cost reductions.

Director Christopher Smith resigned.

Annual meeting approved adding 16 million shares to the equity-incentive plan and reported other votes.

Released Q2 financial results and investor presentation.

Q2 revenue was $187.1 million and adjusted EBITDA grew 125.1% to $35.0 million. Time-charter-equivalent revenue was $18,153/day, up 50% year over year; net debt/trailing adjusted EBITDA was 2.1x.

Removed Eric Rosenfeld, David Sgro and Anthony Laura from the board under the company’s bye-laws; board reduced to seven members.

Reported annual-meeting votes.

Amendment disclosed employment terms for CFO Michael Pena, whose appointment was effective May 1.

Amendment disclosed Dusty Wunderlich’s employment terms; CEO appointment was effective January 27, not August.

Raised approximately $1.301 million through a director/affiliate private placement of 361,385 shares at $3.60, for working capital/general purposes.

Released Q2 results for the quarter ended June 28.

Q2 revenue grew 5.6% to $199.0 million, but same-restaurant sales fell 1.2%. Adjusted EBITDA was $29.8 million versus $30.0 million a year earlier; new restaurants drove reported growth.

Named Kevin Kalicak, formerly an Olive Garden/Darden finance executive, CFO effective September 7.

Extended interim CFO Pamela Smith’s agreement until a permanent replacement or year-end; she also assumed treasurer duties.

Released Q2 results/deck and announced Jim Gute as chief commercial officer.

Q2 revenue rose 34% to $32.9 million but missed management expectations; reported growth includes the enlarged business. Revised the outlook, delayed cash-flow breakeven to 2027 and reduced expected year-end cash to approximately $80 million from $100 million. Quarter-end cash/securities/restricted cash totaled $96.9 million.

Reported annual-meeting votes.

Named Jason Faessler CFO/treasurer, expected to start June 22. The CEO transition is followed by finance and commercial leadership changes.

Amended Stedical’s PermeaDerm distribution/manufacturing agreements: $500,000 fee for first-offer/refusal rights over possible additional territories and revised revenue sharing/minimum payments.

Amendment established annual say-on-pay votes following the shareholder advisory vote.

Released Q2 results.

Q2 net revenue grew 18% to $21.7 million with 81.9% gross margin. Raised 2026 revenue guidance to $86–89 million and targeted Q4 cash-flow breakeven; quarter-end cash and securities were approximately $11.1 million.

Backstopped a proposed $15 million transferable rights offering. Subscription price is the greater of $3.55 or a specified 15-day VWAP through the record date, which was still to be set; the investor group will purchase unsubscribed shares.

Released fiscal Q2 results and announced another CEO transition: Paige Thomas starts September 14; interim CEO Teri Bariquit becomes non-executive chair.

Fiscal Q2 revenue grew 20.8% to $97.7 million; adjusted EBITDA rose to $12.6 million from $3.6 million and net loss narrowed to $12.9 million. The earnings exhibit also announced Paige Thomas as CEO effective September 14, 2026, succeeding interim CEO Teri Bariquit, who becomes non-executive chair.

Agreed to settle IPO-related shareholder litigation, subject to court approval.

Four directors resigned in late August, with related compensation arrangements.

Released Q2 results and announced a restructuring affecting approximately 12% of employees, with estimated $10–11 million charges.

Q2 revenue declined 1.5% to $210.9 million and ARR declined 2.0% to $824.0 million. Free cash flow was $31.9 million. Mohamed prioritized Detection and Response, Exposure Management and a shared AI foundation while reducing headcount.

Reported annual-meeting voting results.

Released Q2 results and updated corporate/earnings presentations.

Genentech advanced the collaboration’s first neuroscience target into an early discovery program. REC-7735 received IND clearance with a Phase 1/2 start planned for the second half; REC-4881 Phase 2 data were planned for November. Lowered 2026 cash operating expense guidance to below $375 million from below $390 million.

Annual meeting elected directors, including Najat Khan, and approved the advisory compensation proposal.

Released Q1 results and updated corporate presentation.

Released Q2 financial results.

Q2 revenue was $33.7 million, including $6.5 million from Alcon and $27.2 million product revenue; cash was approximately $209 million. Withdrew 2026 guidance and expected to resume guidance in early 2027. The exhibit confirms Aziz Mottiwala was serving as CEO.

Appointed Aziz Mottiwala CEO with an expected July 20 start; founder Ron Kurtz moved to chief medical officer.

Preannounced unaudited Q2 financial and operating results.

Released Q2 results.

Q2 U.S. neffy net product revenue was $26.2 million. Casale shifted spending from broad consumer marketing toward high-volume prescribers, with lower second-half operating expenses and targeted cash-flow breakeven by end-2027. CSU Phase 2b interim data were expected in Q1 2027.

Former CEO Richard Lowenthal resigned from the board; CMO Sarina Tanimoto’s employment ended without cause.

Appointed President Donn Casale CEO; Lowenthal’s employment had been terminated without cause.

Added three independent directors: Timothy Adams, Matthew Salzberg and Michael Thompson.

Released Q2 financial results.

Q2 revenue fell 17% to $221.8 million and adjusted EBITDA fell to $65.1 million from $82.2 million. After merger termination, management targeted another $60 million annualized operating-expense reduction by year-end, canceled the scheduled earnings call and declined to issue remaining-2026 guidance.

CAO Steven Ciardiello resigned effective August 28 and the board suspended future quarterly cash dividends.

CFO Nir Naor assumed the principal financial/accounting officer designations; interim officer Francis Brown continued as a consultant.

Released Q2/first-half results and investor presentation.

Q2 revenue rose 9.1% to $41.6 million, including 16.8% growth at Greenbrook. Adjusted EBITDA improved to $0.3 million from a $5.6 million loss; net loss narrowed to $3.4 million. The exhibit confirms Reuvers was serving as CEO.

Announced CFO appointment and other leadership changes, including the chief legal officer’s separation and Greenbrook management promotion.

Announced an approximately 20% workforce reduction, from 201 to 160 employees, and about $1.5 million charges. CFO/COO Roberto Cuca departed; CEO Getz also became principal financial officer.

Amendment formalized former CEO Antony Koblish’s separation agreement.

Released Q2 financial results.

Q2 revenue declined 4% to $19.3 million despite 12% OviTex unit growth. The earnings release states Getz’s CEO appointment was effective August 4; the formal appointment 8-K states August 3. This report uses the formal filing date and flags the discrepancy.

Agreed to return 13 A320neo aircraft early and lease 10 A321neos for delivery in Q4 2026–Q1 2027; expects roughly $260 million reductions in both lease assets and liabilities.

Released Q2 results.

Q2 revenue grew 38% to $1.279 billion and revenue per available seat mile rose 28%. GAAP net loss was $90 million; adjusted net loss was $22 million, excluding early-aircraft-return effects. Total liquidity was $1.16 billion.

Director Nancy Lipson resigned to pursue another opportunity.

Released Q2 earnings and operational update.

Q2 drummed uranium was 140,873 pounds, up 25.7% year over year. Contract deliveries of 215,000 pounds generated $14.4 million product sales; cash cost per pound sold was $40.20 and unrestricted cash was $95.3 million.

Reported annual general/special meeting votes.

Released Q1 earnings and operational update. The input’s TSX ticker URE maps to U.S. URG.

Released Q2 results and supplemental investor materials.

Q2 revenue grew 12% to $263.6 million, with $56.4 million operating cash flow and a $48.2 million net loss. Highlighted seven-year Avis and five-year Hertz contract extensions and revised full-year guidance.

Agreed with Avis on key commercial terms of a new seven-year tolling/violations contract; remaining operating terms still being finalized.

Amendment confirmed annual say-on-pay votes.

U.S. President Pete Suerken announced his departure for purchasing cooperative QSCC; Wendy’s plans to eliminate his role and create a COO position.

Released June-quarter results.

Q2 U.S. same-restaurant sales fell 7.0% and global systemwide sales fell 6.5%. Withdrew the 2026 outlook and reduced the dividend to support the turnaround; adjusted EBITDA was $124.1 million.

Granted International President E.J. Wunsch a $500,000 retention RSU award following Wright’s appointment.

Released Q2 results.

Q2 revenue rose 22% to $1.92 billion but declined 6.5% on a pro forma basis. Adjusted operating income of $203 million includes a $105 million pretax tariff-receivable benefit; free cash flow was $11 million. Raised guidance and the Lexmark gross cost-synergy target to at least $350 million.

Adopted a 2026–2028 transformation retention award plan for executives and other critical employees.

Shareholders approved adding 15 million shares to the equity/performance plan and elected directors, including CEO Pastor.

Signed an approximately $7.675 million stock-and-warrant financing with directors/other existing shareholders: 2.616 million shares plus warrants for 2.355 million shares.

Announced Morris Berger as CEO effective October 1 and outlined the proposed financing, subsequently documented September 10.

Furnished an investor-conference presentation.

Released Q2 financial results.

Q2 sales grew 1.1% to $45.0 million, with pricing offsetting a 3.7% volume decline. Adjusted EBITDA was $0.5 million and net loss was $2.9 million; Ruberti outlined changes to distribution, branding and operating discipline.

Reported annual-meeting votes.

Alexandre Ruberti succeeded Amy Taylor as CEO effective June 15; Taylor retained a board seat.